Kyprolis data fuel Amgen oncology aspirations

Kyprolis data fuel Amgen oncology aspirations

Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.

Biotech Report: Ultra Man

Biotech Report: Ultra Man

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

Lemtrada US rejection snarls Sanofi

Lemtrada US rejection snarls Sanofi

The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.

Iclusig is back in US

Iclusig is back in US

Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Report: Dendreon looking for buyer

The prostate cancer drug company is reportedly seeking a buyer to turn things around.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

OPDP sends Warning Letter to Acorda

The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.